Bedrijfsoverzicht
Alector, Inc. is a clinical stage biotechnology enterprise dedicated to developing therapies designed to counteract the progression of neurodegeneration within the United States market. Operating within the broader healthcare sector and specifically the biotechnology industry, the company focuses on research and development rather than mature product sales, a stage that defines its operational model. The firm employs a workforce of 103 individuals and holds a total market capitalization of $270.39 million, with reported annual revenue for the trailing twelve months standing at $21.05 million. These valuation and revenue figures indicate that the company operates with a relatively small market footprint compared to established pharmaceutical giants, reflecting the high-risk, high-reward nature of early-stage clinical development where revenue generation is currently limited while cash reserves are utilized to fund ongoing research initiatives.
Financiële gezondheid
For the trailing twelve months, the company reported a revenue of $21.05 million, a net income of -$142,928,992, and an EBITDA of -$147,367,008. The substantial disparity between the positive revenue figure and the significant negative net income reveals a cost structure heavily dominated by research and development expenditures, administrative overheads, and clinical trial costs that exceed gross revenues generated. The free cash flow stands at -$114,339,128, which indicates that the company is currently burning cash to sustain its operations and pipeline advancement rather than generating surplus liquidity from its core activities. When analyzing the profitability metrics, the gross margin is recorded at 0.0%, the operating margin is -587.5%, and the profit margin is 0.0%, all of which suggest that the company has not yet achieved sustainable profitability from its sales, a common characteristic for biotechs in the clinical phase where costs are incurred upfront without commensurate revenue. The balance sheet shows a cash position of $256.02 million against total debt of $36.23 million, resulting in a debt-to-equity ratio of 118.22, which implies a highly leveraged capital structure relative to equity, though the absolute debt amount is manageable given the cash on hand. Despite the high debt-to-equity figure, the current ratio of 3.83 suggests that the company maintains a robust short-term liquidity position, possessing sufficient current assets to cover its current liabilities more than threefold. Furthermore, the return on equity is -181.6% and the return on assets is -25.1%, metrics that reveal that management is currently utilizing shareholder capital and assets to generate negative returns, a typical outcome for companies that have not yet commercialized their product portfolio.
Waarderingsbeoordeling
The company presents a trailing P/E ratio of N/A due to its negative net income, while the forward P/E is listed at -2.78, a metric that lacks standard interpretation for loss-making entities but signals the market's pricing of future earnings expectations that remain unprofitable in the short term. The price-to-book ratio is 8.81, indicating that the market values the company at nearly nine times its net asset book value, which suggests a significant market premium applied to the company's intangible assets, including its intellectual property and clinical pipeline potential. Alternative valuation metrics such as the price-to-sales ratio of 12.85 and an EV/EBITDA of -0.34 provide further context, suggesting that investors are valuing the firm primarily on revenue potential and future clinical milestones rather than current earnings or cash flow multiples. In terms of trading range, the stock has a 52-week high of $3.40 and a 52-week low of $0.90, placing the current trading activity within a wide historical band that reflects the inherent volatility of speculative biotechnology stocks. The beta value of 0.58 indicates that the stock price tends to be less volatile than the broader market, moving at approximately 42% of the market's volatility, which offers a relative stability measure for this specific high-risk asset class.
Growth & Income
The company recorded a revenue growth year-over-year of -88.5%, while the earnings growth is listed as N/A due to the absence of profitable earnings to measure growth against. The decline in revenue suggests a contraction in sales, which is typical for a clinical-stage company that may be transitioning between trial phases or facing delays in commercialization timelines. As the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, meaning that all available earnings or cash flows are theoretically available for reinvestment, though in this specific instance, the net loss prevents any actual payout to shareholders. Consequently, the company reinvests its limited resources entirely into research, development, and clinical trials rather than distributing income to shareholders. The overall growth and income profile is characterized by negative revenue expansion and a complete lack of dividend income, reflecting a capital-intensive business model focused on long-term therapeutic breakthroughs rather than immediate financial returns.